Influencing factors when living with Parkinson’s disease: beyond the disease symptomatology
Objective: To identify which are the factors that influence in the process of living with Parkinson's disease (PD). Background: Living with PD is a complex,…On-Demand Treatment Preferences of Patients with Parkinson’s Disease and “OFF” Episodes: Heterogeneity Across Patient Subgroups
Objective: To quantify preference heterogeneity for on-demand treatments among patients with Parkinson’s disease (PD) and “OFF” episodes. Background: Patients with PD commonly experience “OFF” episodes.…Effect of opicapone and entacapone on levodopa short duration response
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy and safety of CX-8998 in T-CALM, a randomized, double-blind, placebo-controlled, phase 2a trial in participants with essential tremor: subgroup analysis by baseline tremor severity
Objective: Evaluate efficacy and safety of CX-8998 in essential tremor (ET) as a function of baseline tremor severity. Background: CX-8998, a selective modulator of T-type…Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France
Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…A pooled analysis of four pivotal, randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: Efficacy as adjunct to levodopa in Parkinson’s disease (PD)
Objective: To determine the efficacy of istradefylline combined with levodopa in PD patients experiencing motor fluctuations in a pooled analysis of 4 pivotal, randomized, placebo-controlled…Opicapone management: A 2-year follow up real- life practice study
Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson’s Disease
Objective: To determine the rates of pharmacological treatment for neuropsychiatric symptoms (NPS) in patients with early Parkinson’s disease (PD), and identify predictors of under-treatment. Background:…Opicapone study in daily clinical practice. OPRA study
Objective: Improvement of off time and increase of ON time without dyskinesias at 6 months compared to the baseline situation. Secondary Endpoints: Determine the rate…Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model
Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 32
- Next Page »